Podcasts about Petros

Money celebrates the Chargers win over the Raiders. Petros and Money discuss a possible show curse over the Dodgers. DVR with Vassegh at Dodger Stadium. Secret Textoso Roundup

Final Hour Fun Fact. Quick Hits. Local Knowledge as Petros has a plan to save UCLA Football. Dead and Alive Guy Birthday of the Day.

Join Chris Chavez, Eric Jenkins, Anderson Emerole, Mitch Dyer and Paul Hof-Mahoney as they recap all the highlights from Day 3 at the 2025 World Championships in Tokyo. Some of today's highlights include:Mondo Duplantis Breaks World Record (6.30m)- Sweden's Mondo Duplantis cleared 6.30m to set his 14th world record- Secured his third straight world title- Vault came on his third and final attempt, capping an electric evening- Historic depth: First time seven men cleared 5.90m+ in a single competition- 2nd: Emmanouil Karalis (GRE) – 6.00m- 3rd: Kurtis Marschall (AUS) – 5.95m (=NR)Beamish Ends El Bakkali's Steeplechase Streak- Geordie Beamish (NZL) wins in a tactical race, kicking late to defeat Soufiane El Bakkali (MAR)- El Bakkali's long championship win streak comes to an end- 1st: Beamish – 8:33.88- 2nd: El Bakkali – 8:33.95- 3rd: Edmund Serem (KEN) – 8:34.56Cole Hocker Disqualified from 1500m Final- Hocker originally finished 2nd in his semifinal- Disqualified for jostling in the final 100 meters- Appeal by USA Track and Field was denied- Disqualification shown on broadcast approximately one hour after the raceDitaji Kambundji Stuns in 100m Hurdles- Swiss hurdler sets a national record (12.24)- Upsets top names including Tobi Amusan- 1st: Kambundji (SUI) – 12.24 NR- 2nd: Tobi Amusan (NGR) – 12.29- 3rd: Grace Stark (USA) – 12.34Simbu Wins Historic Marathon for Tanzania- Alphonce Felix Simbu claims Tanzania's first global gold in the marathon- Outkicked Germany's Amanal Petros by 0.03s- 1st: Simbu – 2:09:48- 2nd: Petros – 2:09:48- 3rd: Iliass Aouani (ITA) – 2:09:53____________PRESENTED BY ASICSFor the third consecutive year, CITIUS MAG is proud to partner with ASICS for our global championship coverage. With their support, we're able to bring you the best coverage of the 2025 World Athletics Championships. Support our sponsor and check out ASICS's latest including the MegaBlast and SonicBlast. Shop at ASICS.com____________Hosts: Chris Chavez | ⁠⁠⁠⁠⁠@chris_j_chavez on Instagram⁠⁠⁠⁠ + Mac Fleet |⁠⁠⁠ ⁠@macfleet on Instagram⁠⁠⁠⁠ + Eric Jenkins | ⁠⁠_ericjenkins on Instagram⁠⁠ + Anderson Emerole | ⁠⁠@atkoeme on Instagram⁠⁠ + Mitch Dyer | ⁠⁠@straightatit_ on Instagram⁠⁠ + Paul Hof-Mahoney | ⁠⁠@phofmahoney on Instagram⁠⁠Produced by: Jasmine Fehr |⁠⁠⁠ ⁠@jasminefehr on Instagram

The guys are fired up for a big sports weekend with the Dodgers in SF taking on the Giants. Petros is in Logan, Utah for a college football games. DVR with Vassegh from Oracle Park. Secret Textoso Roundup.

Number, Word and Song of the Day. Petros with a College Football Whip Around. Lessons Learned in Great Sportstalk 

Number, Word and Song of the Day. Petros with a F1 Report. PMS Pick Six and Secret Textoso Roundup

This week on 2 Pros and a Cup of Joe, Bill Belichick gets embarrassed in his debut for North Carolina. The Olp, Petros stops by and the NNFL season opener get hijacked by a couple of spitters.See omnystudio.com/listener for privacy information.

Petros with the PMS Pick 6. Number, Word and Song of the Day. Matt Smith checks in from Brazil. Dead and Alive Guy Birthday of the Day.

A FLEX ALERT before the Dodgers game in Baltimore. Petros is joined by BFF Don MacLean. What to make of this Clippers and Ballmer story. College Football Whip Around. DVR with Vassegh with the latest on why Tyler Glasnow was scratched from his start.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Petros and Don MacLean with a FLEX ALERT before the Dodgers-Pirates game in Pittsburgh. DVR with Vassegh. A report that the Clippers and Kawhi Leonard used a fraudulent Tree Company to circumvent the Salary Cap

A FLEX ALERT before the Dodgers-Pirates game in Pittsburgh. Petros says goodbye to Matt, who is off to Brazil with the Chargers. DVR with Vassegh. How Was Your Weekend?

Petros Papadakis of Fox Sports Radio in Los Angeles joins Dave Softy Mahler from Dodger Stadium to talk about being there with a bobblehead giveaway happening, the Dave Portnoy situation with Fox Sports, and then a connection issue interrupts them.See omnystudio.com/listener for privacy information.

Description: Ten members of a major burglary crew tied to at least 92 break-ins across Los Angeles have been arrested in a sweeping multi-agency bust. Conway then shared a wild story about Huell Howser, who once sued him for using adult film music under clips of his classic TV show and even nearly fought him at Pink's Hot Dogs—unlike Kevin and Bean, who eventually made peace with Conway, Huell never did. The Petros and Money Show, nicknamed the WienerLords of LA, have now enlisted Sweet James Bergener to sue Conway over claims that he wrongfully took credit for inventing Hot Dog Day. Conway closed the segment with his fiery rebuttal to their cease-and-desist letter. 5:05pm – Ten members of a major burglary crew tied to at least 92 burglaries in Los Angeles have been arrested following a major multi-agency bust last week, city leaders announced. 5:20pm – Huell Howser sued Conway for using porn music under classic lines from his old TV shows, and almost got beat up by him at Pinks Hot Dogs. Kevin and Bean used to have issues with Conway... until they met him. But Huell Howser??? Nope! 5:35pm – The WienerLords of LA (aka The Petros and Money Show) tap the legal services of Sweet James Bergener to file a lawsuit against Conway for issues related to Hot Dog Day, which Conways claims to have invented.  5:50pm – Conway's rebuttal to the cease & desist letter from The Weiner Lords  

Petros and Money are at Vans in Costa Mesa for the 6th and Final Stop of the PMS Summer Tour. John Stevens the mayor of Costa Mesa. Fox Sports College Football Analyst Joel Klatt stops by to vist the boys.

Petros and Money are at Vans in Costa Mesa for the 6th and Final Stop of the PMS Summer Tour. DVR with Vassegh from Petco park in San Diego. Fox Sports NFL Analyst Mark Sanchez stops by and vists with the guys at Vans. 

Petros and Money are at Vans in Costa Mesa for the 6th and Final Stop of the PMS Summer Tour. Steve Van Doren welcomes the guys. Top Story of the Day. Henrik from BBQ Galore.

Petros and Money are at Vans in Costa Mesa for the 6th and Final Stop of the PMS Summer Tour. Time to give away $5k and prizes to the Summer Tour Finalists. Goodbye and Thank Your making the PMS Summer Tour the best yet!

Petros Papadakis from Fox Sports in Los Angeles joins Dave Softy Mahler to talk about his ranking as one of the worst football broadcasters, the varying degrees of access in college programs and dysfunction at UCLA, and the start of the college football season.See omnystudio.com/listener for privacy information.

Petros and Matt are BACK after a Dodgers sweep against the Padres. Top Story of the Day. How Was Your Weekend? 

Petros Tsitsipas has spent most of his career carving out a place on the doubles tour, often alongside his brother Stefanos, but in recent months, he has been shifting his focus back to singles. I recently had the chance to sit down with him for a long conversation about life on tour, the unique dynamic of playing with siblings, the changing nature of doubles, and, of course, his gear.

 A Flex Alert as the guys are LIVE from Brewery X in Anaheim for Stop #4 of the PMS Summer Tour. Angels Analyst Mark Gubicza comes over from the Big A to talk some Freeway Series. Great Sports Talk and State of Dodgers from Petros.

The Foosh thanks everyone for all the love and donations. The Woody Show talks about the Foosh. Petros & Money talks about the accident                                                                 Levi Ostfeld with Roof Buddy on the necessity of a good roof.  Water back on in Granada Hills and Porter Ranch  

CLL #2574 (feat. Matt ‘Money’ Smith) 08/10/2005 – Wednesday Night Show Source – Official VHS Tape (2025)  This episode is 100% complete with a major audio upgrade. Matt from ‘Petros and Money’ is filling in for Adam. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. https://adamanddrdrewshow.com/1743-loveline-nostalgia-with-superfan-giovanni/ https://account.venmo.com/u/GiovanniGiorgio Paid Link – As an Amazon Associate I earn from qualifying purchases. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

Word,number,song of the day. Former Angel, Tim Salmon, joins the show to talk about Dodgers Angels rivalry. Petros and Matt talk about a "nothing story". 

Tim Cates talks about Ice Cube's suprise visit to the iHeart studio in Burbank. Former USC QB Todd Marinovich talks to Petros and Matt. Secret textoso. 

Dodgers pitcher Anthony Banda joins the show LIVE. Talks with Petros and Matt about upbrining in small town Texas, Dodgers locker room and bullpen, and anime. 

Petros Papadakis of Fox Sports Radio in Los Angeles joins Dave Softy Mahler to talk about Lincoln Riley’s job security at USC, the Trojans’ program overall, another WNBA incident taking place, the buzz around Dawgs football and the opening game broadcast.See omnystudio.com/listener for privacy information.

Petros and Matt react to the Dodgers fans cheering for Mookie Betts to show their support for the struggling SS. Top Story of the Day on Mookie and a wild idea from a fan to change his bat. John Minter owner of Glomar Bats. 

Read OnlineThen Peter took Jesus aside and began to rebuke him, “God forbid, Lord!  No such thing shall ever happen to you.” He turned and said to Peter, “Get behind me, Satan!  You are an obstacle to me. You are thinking not as God does, but as human beings do.” Matthew 16:22–23What a shocking statement this must have been that was spoken by Jesus to Peter. “Get behind me, Satan!” Jesus said. In the paragraph before this, Peter professed that Jesus was “the Christ, the Son of the living God.” Jesus in turn told Peter that he was Petros and on this petra He would build His Church. Petros is the Greek word for a movable rock and petra was an immovable solid rock foundation. Thus, Peter was told that he would be the stone, set upon a solid foundation, by which Jesus would build His Church. Jesus even went on to promise Peter that he would receive the keys to the Kingdom and that whatever he bound on earth would be bound in Heaven. And then, one paragraph later, Jesus rebukes Peter for thinking “not as God” but as a human being.Jesus rebuked Peter because Peter could not accept Jesus' teaching about His coming passion and death. Jesus told Peter and the other disciples that He would soon suffer greatly, be rejected by the chief priest, the scribes and the elders, be killed and then rise on the third day. So Peter went from a profound proclamation of faith, to fear and a rejection of the divine plan of salvation. And for that reason, Jesus went from entrusting much authority to Peter to rebuking him for his weakness and fear.Fear is often a paralyzing passion. Saint Thomas Aquinas explains that the passion of fear comes from a perceived future evil. Sorrow is the normal reaction to a present suffering such as the death of a loved one. But when the perceived suffering, or apparent evil, is something that has not yet come, then we often react with fear. When that fear is caused by something exterior and out of our control, it tempts us to feel shock, a sense of being overwhelmed and anxiety. In the case of Peter, the thought of Jesus suffering greatly, and being killed, was more than he was able to accept. So Peter says, “God forbid, Lord! No such thing shall ever happen to you.”Jesus' rebuke of Peter was an act of true love. It was a way of shaking him free from the paralysis of fear. Jesus wanted Peter to think clearly and to face this future suffering with courage, acceptance, hope and faith. Courage provides strength. Acceptance cures anxiety. Hope produces joy. And faith is the remedy for all fear. These and other similar virtues were necessary if Peter and the other disciples were going to be able to endure the suffering and passion of Jesus. They needed to know that this perceived evil was going to be transformed by the Father in Heaven and used for the greatest good the world had ever known. They needed to know that Jesus “must go to Jerusalem and suffer greatly…” It was the Father's will. And because it was the Father's will, the greatest good would come from the greatest evil because of God's almighty power. Reflect, today, upon that which causes you the most fear and anxiety in your life. When you look to the future, what is it that paralyzes you or at least tempts you to fear and worry? The truth is that any evil or suffering that you foresee has the potential to bring forth the greatest good in your life. Your natural human mind cannot discern this. We must strive to think as God, not as humans, as Jesus says. Try to look at anything that causes you anxiety through the eyes of God alone. Trust that, in faith, all can be used by God for good. Do not doubt but believe and God will begin to bestow upon you the many virtues you need to move forward with peace, courage and confidence. My suffering Lord, You faced the evil You endured with the utmost courage and love. You never gave in to fear but pressed on, fulfilling the Father's will. Give me the grace I need to share in Your strength so as to overcome all that tempts me to fear. I love You, my Lord. May I rely upon You for all things. Jesus, I trust in You.Image: National Trust, Public domain, via Wikimedia CommonsSource of content: catholic-daily-reflections.comCopyright © 2025 My Catholic Life! Inc. All rights reserved. Used with permission via RSS feed.

Petros and Money are LIVE at The Bolt in El Segundo for Chargers Training Camp. Rashawn Slater and Tre Harris join the guys after practice. Great Sports Talk as David Vassegh is trying to get Dodgers fans to rally around Mookie Betts. How Was Your Weekend?

A FLEX ALERT before the Dodgers-Rays game in Tampa Bay. Petros and Matt react to the Dodgers moves at the Trade Deadline. Top Story of the Day on the Chargers and Hall of Fame Game. Lessons Learned in Great Sports Talk

A FLEX ALERT with Petros and Tim Cates as the countdown is on for the MLB Trade Deadline. Number, Word and Song of the Day. The Dodgers make a move minutes before the buzzer sounds, but other teams in the NL also made moves to bolster their rosters.

The MLB Trade Deadline has passed and Petros and Tim recap the flurry of trades. DVR with Vassegh in Tampa Bay with the Dodgers. Dead and Alive Guy Birthday of the Day.

A FLEX ALERT before the Dodgers-Reds game in Cincinnati. Petros is joined by Jonas Knox. Reaction to the excessive Tusnami Warnings last night. DVR with Vassegh with the latest on the MLB Trade Deadline. Wild 48 hours for the WNBA.

A FLEX ALERT before the Dodgers-Reds games in Cincinnati. Luka showed the world he is skinny, so LeBron showed the world on IG he is working out hard too. DVR with Vassegh from Cincy. Petros with a PMS Film Noir Corner

A FLEX ALERT before the Dodgers-Reds game in Cincinnati. Petros has discovered video games in 2025 and how different they are from the 80's. Tim Cates says he saw the worst movie ever. Top Story of the Day. How Was Your Weekend?

Tim Conway Jr. kicks off the show with the sad news of Hulk Hogan's passing at 71—and in true Conway fashion, honors him by bringing in a hot dog steamer. Petros & Money swing by with an update on The Duke of Sports dating contest, and later, Tim reveals that Jay Leno once wrestled Hulk Hogan (!), and the two are now teaming up to sell cars—Tim heads up the “cream puff” division. The hot dog party heats up as ketchup controversies and bathroom habits take center stage. Then, it's back to business with updates on the Encino crime patrol, a shoutout to AM 570 for the hot dog inspiration, and a preview of Dine LA 2025 at JW Marriott, including a plug for local favorite Savoca. 

Tim opens Hour 2 with tales from the return counter—Costco style—and shares wild audio of a customer seriously milking the store's famously generous policy. Then it's back to Tim's war on bad nicknames, as he laments the rise of “Cali” while doubling down on Mayor Bass's beloved “Angelenos.” From there, it's Christmas in July at Hobby Lobby, and Tim shares his surprising depth of tariff knowledge (and deep offense at premature holiday shopping). Later, Tim gets roasted on AM 570's Petros and Money Show for his hot dog steamer purchase and gives one more shoutout to the real star of the night—those finely chopped onions. Finally, he revisits the latest mockery of The Duke of Sports and his misadventures in the Gary and Shannon dating game.

Petros and Money talk USC UCLA BIG 10 Media Day. WWE Hall of Famer Ted DiBiase talks about the late Hulk Hogan's legacy. 

The guys are joined by Petros Papadakis as they break down the college football landscape, the Dodgers not playing up to their abilities, the biggest questions leading into NFL Training Camp, Coop's Leftovers, and more!See omnystudio.com/listener for privacy information.

Petros and Matt discuss the Dodgers getting swept by the Brewers last weekend. Local knowledge. How Was Your Weekend? 

Matt and George have your word, number and song of the day plus Jose Mota joins to talk Dodgers and Petros is on after leaving las vegas!

Matt and DMac is in for P, but they talk to Petros and new Clipper Brook Lopez joins the show!

The Old P, Petros Papadakis stops by to relive the MLB All-Star Game! Terry McClaurin airs out his frustration but the Commanders are right to be hesitant with his new contract. Plus, National Hot Dog Day on Lee’s Leftovers.See omnystudio.com/listener for privacy information.

Petros and Money talk about the All-Star game, give a Superman review and discuss Shaq's podcast. 

Petros and Money give you a fun fact and then Quick Hits plus Dead and Alive Guy!

Petros and Money talk about the state of college football, talk Lakers and LeBron with Mark Medina and debate LeBron's Lakers tenure with Adam Auslund. 

Petros and Money review the Joe Kelly interview, talk about the Dodgers Giants series and How Was Your Weekend?